InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Discover the complete record of transactions filed by Shah Preetam, Chief Financial Officer. Director active across 1 company, notably Cidara Therapeutics, Inc.. In total, 3 reports have been published. Split: 2 buys · 0 sell. Total volume traded: €54k. History available since 12 November 2021. The latest transaction was filed on 31 March 2022 (Attribution). Regulator: SEC (Form 4). All data is free.
Declarations3 total
51,250 shares0Common StockSEC:0001610618-22-000029:0
20,000 shares@ US$1.5450.0% of flowCommon StockSEC:0001610618-21-000106:0
Ideal exit: 9 Aug 2022 (T+270)
20,000 shares@ US$1.54100.0% of flowCommon StockSEC:0001610618-21-000106
Ideal exit: 9 Aug 2022 (T+270)
3 of 3 declarations
About Shah Preetam
Preetam Shah serves as Chief Financial Officer and Chief Business Officer at Cidara Therapeutics, Inc. In this role, he oversees the financial and business functions of the company. Cidara Therapeutics, Inc. is a biopharmaceutical company specializing in developing innovative treatments. Shah plays a key role in financial and business strategy, thereby contributing to the company's growth and sustainability.
